← Eichor
Study identifier: NCT07612163 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients

Condition: Bacterial Infections  ·  Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

PhaseN/A
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Patients may benefit from the personalized β-lactams dosing strategy based on pharmacokinetics. The objective of this study is to retrospectively review, prospective observe and analyze the clinical outcomes of patients with liver cirrhosis, and to build a population pharmacokinetics model in the population mentioned above.

This description comes directly from the study's public registry record.

Talk to the study team

Dayu Chen  ·  +862583106666  ·  cdy_pharmacy@njglyy.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNanjing, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07612163